Neylan John F. 4
4 · KERYX BIOPHARMACEUTICALS INC · Filed Oct 30, 2018
Insider Transaction Report
Form 4
Neylan John F.
Chief Medical Officer
Transactions
- Sale
Common Stock
2018-10-29$3.07/sh−1,253$3,847→ 149,435 total
Footnotes (2)
- [F1]Sale of a total of 1,253 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on October 28, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
- [F2]Includes 70,102 shares of restricted stock.